Grace Therapeutics, Inc. (GRCE) — Cash Flow-to-Debt Ratio
Grace Therapeutics, Inc. (GRCE) has a Cash Flow-to-Debt Ratio of -0.62x as of December 2025, meaning its operating cash flow of $-2.22 Million could theoretically repay -1% of its total liabilities ($3.60 Million) in one year. See Grace Therapeutics, Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Grace Therapeutics, Inc. Cash Flow-to-Debt Ratio (2010–2025)
Historical debt coverage capacity for Grace Therapeutics, Inc. across 15 annual periods. For the full cash flow conversion analysis, see Grace Therapeutics, Inc. cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Grace Therapeutics, Inc. (2010–2025)
Year-by-year debt coverage analysis for Grace Therapeutics, Inc.. Check earnings quality score of Grace Therapeutics, Inc. to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.77x | $-14.90 Million | $5.38 Million | ▼ -159.5% |
| 2024 | -1.07x | $-12.33 Million | $11.56 Million | ▲ +25.1% |
| 2023 | -1.42x | $-15.91 Million | $11.17 Million | ▼ -68.2% |
| 2022 | -0.85x | $-17.23 Million | $20.35 Million | ▲ +59.8% |
| 2021 | -2.11x | $-14.32 Million | $6.80 Million | ▲ +9.5% |
| 2020 | -2.33x | $-22.95 Million | $9.86 Million | ▼ -142.8% |
| 2019 | -0.96x | $-24.79 Million | $25.85 Million | ▼ -12.9% |
| 2018 | -0.85x | $-9.69 Million | $11.41 Million | ▲ +83.2% |
| 2016 | -5.07x | $-4.85 Million | $957.12K | ▼ -180.2% |
| 2015 | -1.81x | $-5.75 Million | $3.18 Million | ▼ -228.3% |
| 2014 | -0.55x | $-6.12 Million | $11.10 Million | ▲ +47.1% |
| 2013 | -1.04x | $-2.49 Million | $2.39 Million | ▲ +76.6% |
| 2012 | -4.46x | $-5.65 Million | $1.27 Million | ▼ -1120.5% |
| 2011 | -0.37x | $-1.91 Million | $5.24 Million | ▲ +6.2% |
| 2010 | -0.39x | $-1.90 Million | $4.88 Million | — |